Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Melanoma 1Margins of Excision 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Rituximab 43Cyclophosphamide 41fludarabine phosphate 24Filgrastim 19fludarabine 16Lenalidomide 15Bendamustine Hydrochloride 15Peripheral Blood Stem Cell Transplantation 14Bortezomib 13Etoposide 11venetoclax 10ibrutinib 10Radiotherapy 10Biopsy 10aldesleukin 9Vincristine 9Prednisone 9Magnetic Resonance Spectroscopy 9Vorinostat 8Specimen Handling 8Cytarabine 8Cyclosporine 8pembrolizumab 7obinutuzumab 7Paclitaxel 7Gemcitabine 7Flow Cytometry 7tanespimycin 6Tacrolimus 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Follicular × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡